Avicanna (AVCN) investor relations material

Strategic focus and business model

• Focuses on medical and pharmaceutical applications of cannabinoids, operating through four commercial pillars: medical portfolio (RHO Phyto), pharmaceutical pipeline, raw material division, and digital care platform (MyMedi).

• Operates an asset-light, biopharmaceutical model, leveraging partnerships with academic and clinical institutions in Canada.

• International presence in over 20 markets, with expansion contingent on regulatory changes, especially in the U.S.

• Owns all intellectual property related to drug development, formulations, and clinical methodologies.

Product innovation and commercialization

• RHO Phyto offers over 60 non-inhaled, advanced cannabinoid-based SKUs, with a focus on physician-guided, indication-specific formulations.

• Recently launched QUIX, a proprietary nanotechnology for fast-onset, accurately dosed cannabinoid products, aiming to reduce reliance on inhaled products.

• MyMedi.ca, acquired from Shoppers Drug Mart, serves as a comprehensive online pharmacy and patient support platform, integrating pharmacists and medical affairs.

• Integration with hospitals and multidisciplinary clinics is expanding, with pilots underway and protocols being standardized for broader adoption.

Clinical development and data-driven approach

• Pharmaceutical pipeline includes six major candidates, with one in phase II for osteoarthritic pain and another in phase I for PTSD; Trunerox for epilepsy launched in Colombia.

• Real-world evidence from MyMedi and RHO Phyto informs product development and clinical protocols, with published data in peer-reviewed journals.

• Clinical trials are supported by Canadian government grants and partnerships with leading institutions like Toronto General Hospital and UHN.

• Plans to monetize clinical data and expand licensing opportunities, especially as U.S. regulations evolve.